407 related articles for article (PubMed ID: 18212337)
1. Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy.
Johnston S; Trudeau M; Kaufman B; Boussen H; Blackwell K; LoRusso P; Lombardi DP; Ben Ahmed S; Citrin DL; DeSilvio ML; Harris J; Westlund RE; Salazar V; Zaks TZ; Spector NL
J Clin Oncol; 2008 Mar; 26(7):1066-72. PubMed ID: 18212337
[TBL] [Abstract][Full Text] [Related]
2. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas.
Burris HA; Hurwitz HI; Dees EC; Dowlati A; Blackwell KL; O'Neil B; Marcom PK; Ellis MJ; Overmoyer B; Jones SF; Harris JL; Smith DA; Koch KM; Stead A; Mangum S; Spector NL
J Clin Oncol; 2005 Aug; 23(23):5305-13. PubMed ID: 15955900
[TBL] [Abstract][Full Text] [Related]
3. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
Medina PJ; Goodin S
Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
[TBL] [Abstract][Full Text] [Related]
4. Phase II study to evaluate the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer.
Boussen H; Cristofanilli M; Zaks T; DeSilvio M; Salazar V; Spector N
J Clin Oncol; 2010 Jul; 28(20):3248-55. PubMed ID: 20530274
[TBL] [Abstract][Full Text] [Related]
5. Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer.
Tevaarwerk AJ; Kolesar JM
Clin Ther; 2009; 31 Pt 2():2332-48. PubMed ID: 20110044
[TBL] [Abstract][Full Text] [Related]
6. Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer.
Ross HJ; Blumenschein GR; Aisner J; Damjanov N; Dowlati A; Garst J; Rigas JR; Smylie M; Hassani H; Allen KE; Leopold L; Zaks TZ; Shepherd FA
Clin Cancer Res; 2010 Mar; 16(6):1938-49. PubMed ID: 20215545
[TBL] [Abstract][Full Text] [Related]
7. Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies.
Spector NL; Xia W; Burris H; Hurwitz H; Dees EC; Dowlati A; O'Neil B; Overmoyer B; Marcom PK; Blackwell KL; Smith DA; Koch KM; Stead A; Mangum S; Ellis MJ; Liu L; Man AK; Bremer TM; Harris J; Bacus S
J Clin Oncol; 2005 Apr; 23(11):2502-12. PubMed ID: 15684311
[TBL] [Abstract][Full Text] [Related]
8. Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study.
Kaufman B; Trudeau M; Awada A; Blackwell K; Bachelot T; Salazar V; DeSilvio M; Westlund R; Zaks T; Spector N; Johnston S
Lancet Oncol; 2009 Jun; 10(6):581-8. PubMed ID: 19394894
[TBL] [Abstract][Full Text] [Related]
9. HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer.
Press MF; Finn RS; Cameron D; Di Leo A; Geyer CE; Villalobos IE; Santiago A; Guzman R; Gasparyan A; Ma Y; Danenberg K; Martin AM; Williams L; Oliva C; Stein S; Gagnon R; Arbushites M; Koehler MT
Clin Cancer Res; 2008 Dec; 14(23):7861-70. PubMed ID: 19047115
[TBL] [Abstract][Full Text] [Related]
10. Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trial.
Ravaud A; Hawkins R; Gardner JP; von der Maase H; Zantl N; Harper P; Rolland F; Audhuy B; Machiels JP; Pétavy F; Gore M; Schöffski P; El-Hariry I
J Clin Oncol; 2008 May; 26(14):2285-91. PubMed ID: 18467719
[TBL] [Abstract][Full Text] [Related]
11. Lapatinib and ixabepilone for the treatment of metastatic breast cancer.
Halterman PA
Pharmacotherapy; 2008 Oct; 28(10):1255-66. PubMed ID: 18823221
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer.
Gomez HL; Doval DC; Chavez MA; Ang PC; Aziz Z; Nag S; Ng C; Franco SX; Chow LW; Arbushites MC; Casey MA; Berger MS; Stein SH; Sledge GW
J Clin Oncol; 2008 Jun; 26(18):2999-3005. PubMed ID: 18458039
[TBL] [Abstract][Full Text] [Related]
13. Synergistic inhibition of breast cancer cell lines with a dual inhibitor of EGFR-HER-2/neu and a Bcl-2 inhibitor.
Witters LM; Witkoski A; Planas-Silva MD; Berger M; Viallet J; Lipton A
Oncol Rep; 2007 Feb; 17(2):465-9. PubMed ID: 17203189
[TBL] [Abstract][Full Text] [Related]
14. A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma.
Wülfing C; Machiels JP; Richel DJ; Grimm MO; Treiber U; De Groot MR; Beuzeboc P; Parikh R; Pétavy F; El-Hariry IA
Cancer; 2009 Jul; 115(13):2881-90. PubMed ID: 19399906
[TBL] [Abstract][Full Text] [Related]
15. Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study.
Finn RS; Gagnon R; Di Leo A; Press MF; Arbushites M; Koehler M
J Clin Oncol; 2009 Nov; 27(33):5552-8. PubMed ID: 19858400
[TBL] [Abstract][Full Text] [Related]
16. Lapatinib activity in premalignant lesions and HER-2-positive cancer of the breast in a randomized, placebo-controlled presurgical trial.
Decensi A; Puntoni M; Pruneri G; Guerrieri-Gonzaga A; Lazzeroni M; Serrano D; Macis D; Johansson H; Pala O; Luini A; Veronesi P; Galimberti V; Dotti MC; Viale G; Bonanni B
Cancer Prev Res (Phila); 2011 Aug; 4(8):1181-9. PubMed ID: 21685235
[TBL] [Abstract][Full Text] [Related]
17. Lapatinib-associated toxicity and practical management recommendations.
Moy B; Goss PE
Oncologist; 2007 Jul; 12(7):756-65. PubMed ID: 17673607
[TBL] [Abstract][Full Text] [Related]
18. Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel.
Millar EK; Graham PH; O'Toole SA; McNeil CM; Browne L; Morey AL; Eggleton S; Beretov J; Theocharous C; Capp A; Nasser E; Kearsley JH; Delaney G; Papadatos G; Fox C; Sutherland RL
J Clin Oncol; 2009 Oct; 27(28):4701-8. PubMed ID: 19720911
[TBL] [Abstract][Full Text] [Related]
19. The predictive value of EGFR and HER-2/neu in tumor tissue and serum for response to anthracycline-based neoadjuvant chemotherapy of breast cancer.
Schippinger W; Dandachi N; Regitnig P; Hofmann G; Balic M; Neumann R; Samonigg H; Bauernhofer T
Am J Clin Pathol; 2007 Oct; 128(4):630-7. PubMed ID: 17875515
[TBL] [Abstract][Full Text] [Related]
20. Microvessel density, expression of estrogen receptor alpha, MIB-1, p53, and c-erbB-2 in inflammatory breast cancer.
McCarthy NJ; Yang X; Linnoila IR; Merino MJ; Hewitt SM; Parr AL; Paik S; Steinberg SM; Hartmann DP; Mourali N; Levine PH; Swain SM
Clin Cancer Res; 2002 Dec; 8(12):3857-62. PubMed ID: 12473600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]